The Research Advances of Aptamers in Hematologic Malignancies

Abstract

Currently, research for hematological malignancies is very intensive, with many breakthroughs. Among them, aptamer-based targeted therapies could be counted. Aptamer is a targeting tool with many unique advantages (easy synthesis, low toxicity, easy modification, low immunogenicity, nano size, long stability, etc.), therefore many experts screened corresponding aptamers in various hematological malignancies for diagnosis and treatment. In this review, we try to summarize and provide the recent progress of aptamer research in the diagnosis and treatment of hematologic malignancies. Until now, 29 aptamer studies were reported in hematologic malignancies, of which 12 aptamers were tested in vivo and the remaining 17 aptamers were only tested in vitro. In this case, 11 aptamers were combined with chemotherapeutic drugs for the treatment of hematologic malignancies, 4 aptamers were used in combination with nanomaterials for the diagnosis and treatment of hematologic malignancies, and some studies used aptamers for the targeted transportation of siRNA and miRNA for targeted therapeutic effects. Their research provides multiple approaches to achieve more targeted goals. These findings show promising and encouraging future for both hematological malignancies basic and clinical trials research.

The impact of circulating 25-hydroxyvitamin D and vitamin D receptor variation on leukemia-lymphoma outcome: Molecular and cytogenetic study

“…They are frequently considered to have been formed as a result of improper growth of blood and lymphatic cells throughout different phases of development or differentiation. They comprise nearly 6.5 % of the total number of malignancies globally ( Liao et al, 2023 ). Leukemia and lymphoma are two distinct forms of hematological malignancies ( Enawgaw et al, 2021 ).…”

“…It can be subdivided into four major subgroups in accordance with the kind of cell affected: chronic or acute, and myeloid or lymphoid leukemia ( Ali and Salih, 2021 ). In the vast majority of patients with Chronic Myeloid Leukemia (CML), the cancer is caused by abnormal transmission between chromosomes 9 and 22, creating the chimeric fusion gene BCR-ABL, the so-called Philadelphia (Ph) chromosome ( Liao et al, 2023 ). More than 90 % of cases are caused by the Philadelphia chromosome ( Selene et al, 2023 ).…”

Development and Validation of Aptasensor Based on MnO2 for the Detection of Sulfadiazine Residues

“…Aptamers are single-stranded DNA (ssDNA) or RNA that specifically bind to target molecules. Aptamers have superior stability, excellent affinity, strong specificity, and easy in vitro screening compared to antibodies [ 12 , 13 , 14 ]. With these advantages, various aptamer-based sensors have been widely developed for environmental monitoring and food safety inspection (e.g., fluorescent, electrochemical, surface-enhanced Raman scattering, and photoelectrochemical sensing signals) [ 15 , 16 , 17 ].…”